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Constructing a Georgia Surveillance System for Hemoglobinopathies Using
Multiple Data Sets: The First Step towards a Comprehensive Prevention and Service Delivery Strategy
Angela Snyder, Ph.D., M.P.H ; Mei Zhou, M.S.; Jane Branscomb, M.P.H*

RESEARCH OBJECTIVE

To construct a hemoglobinopathy surveillance system to determine the annual
incidence and five-year prevalence (2004-2008) of hemoglobinopathies in Georgia
and to describe the demographics of the populations living with these disorders.

Figure 2: Georgia newborns screening positive for sickle cell
disease, January 2004 through December 2008

STUDY DESIGN
The surveillance system of hemoglobinopathy combines data from five data
sources: (1)State Newborn Screening Program (NBS); (2)Georgia hospital discharge
file, including most in-patient and emergency room visits in the state; (3) Grady,
CHOA and GHSU health systems, including all outpatient visits; (4) State Medicaid
and CHIP programs; and (5) State Health Benefit Plan (SHBP). Laboratory screening
and confirmatory results, coupled with clinical expertise, are used to confirm cases
from NBS, Grady, CHOA and GHSU data. ICD-9, CPT and NDC codes are used to
identify probable and possible cases from additional administrative datasets.

CONCLUSIONS
The new surveillance system of hemoglobinopathies provides first hand estimates of the
prevalence and geographic profile of the diseased population in Georgia. It can also be
exploited to test the validity of using administrative data for health services research of
sickle cell disease. This type of surveillance system is essential for the Georgia
Department of Public Health to craft an effective service delivery strategy to a targeted
population and prevent associated complications and healthcare utilization which may
arise from unmanaged disease.

A probabilistic matching method is adopted to merge all datasets and remove
duplicate records. Each data source contains different data elements that can be
used to link the records. Variables used in linking include but are not limited to
patient’s name, date of birth, sex, county, zip code, mother’s name, phone number,
and address. Records are compared on each of the specified variables and a weight
is generated for each potential match to reflect the strength of agreement.

POPULATION STUDIED
Individuals with clinical or laboratory indication of sickle cell disease who lived in
Georgia between 2004 and 2008.

PRINCIPAL FINDINGS
From 2004 through 2008, 829 newborns screened positive for a sickle cell disorder
in Georgia with 85 percent of them having a confirmed diagnosis (Figure 1). Slightly
over half of the newborns were diagnosed with SS or S Beta Zero Thalassemia and
about one quarter Sickle C disease. Using newborn screening data from 2004
through 2008 (Figure 2), we identified the counties with the highest number of
incident cases. Most cases are found in the five metro Atlanta counties (Fulton,
DeKalb, Cobb, Gwinnett and Clayton) as well as the smaller metropolitan areas in
South and Southeastern Georgia.

We find 4,443 unique individuals (1,795 adults and 2,646 children) treated for a
hemoglobinopathy in Georgia from 2004 through 2008 when merging all clinical and
NBS data. More than 97 percent of these individuals have a confirmed diagnosis. We find
20,939 possible cases when merging the administrative datasets: Medicaid, SHBP, and
Hospital discharge data with 36 percent of the Medicaid members overlapping with the
hospital discharge file and 52 percent of the individuals identified through hospital
discharge data overlapping with Medicaid. Twenty-one percent of the SHBP members
were also found in the Hospital discharge file. While the next step is to merge and
deduplicate the clinical and administrative data sets, we estimate that up to 47 percent of
the individuals identified through state hospital discharge data may also be present in
one of the three clinical systems.

During that same time period, CHOA treated approximately 1,490 pediatric patients
with a hemoglobin disorder, and Grady and GHSU treated approximately 1,674 and
1,256 patients, respectively. Medicaid and CHIP programs paid claims for
approximately 14,667 enrollees with a hemoglobinopathy-associated medical
encounter, while the SHBP covered such services for 1,474 enrollees. Lastly, close to
10,097 individuals were treated in a Georgia emergency room or hospital for a
hemoglobinopathy (Figure 3).

Figure 3: Overlap between health insurance claims data and
Georgia hospital discharge data
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IMPLICATIONS FOR POLICY, DELIVERY OR
PRACTICE
Early outcomes from this project have allowed us to identify areas to focus
hemoglobinopathy prevention and outreach efforts. Further progress will allow us to
answer programmatic, policy, and research questions specific to Georgia, and aid in the
development of educational materials for providers, policy-makers and legislators.
Lessons learned can be shared with other states interested in developing similar
surveillance systems and shared with the health services research community who
typically use administrative data for epidemiologic research.

This poster was supported by Cooperative Agreement 5U50DD000582-02 from
the Centers for Disease Control and Prevention (CDC). Its contents are solely the
responsibility of the authors and do not necessarily represent the official views of CDC.
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Figure 1: Incident cases of sickle cell disease by genotype
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